… We enrolled all infectious disease patients who were managed with concurrent PIPC/TAZ
and VCM. The record of dosage and the administration interval of each antibiotic and its …

… , piperacillin-tazobactam, or carbapenems could be inappropriate for cancer patients with …
In this study we used the C/T limited dose of 1.5 g every 8 hours given that the 3-g dose was …

… with EI compared with SI of piperacillin– tazobactam (3.375 g … of 8 or 16 mg/L. However,
bacterial killing at the end of the … evaluated 117 morbidly obese patients (mean BMI 46.95 kg/…

… doses based on TDM was found for either meropenem or piperacillin tazobactam although
mean daily doses … focusing on piperacillin-tazobactam TDM in severely obese ICU patients …

… critically ill patients receiving meropenem, piperacillin/tazobactam and … dose in patients
with various renal function. A PTA for ≥ 90% of patients was obtained for the 2000/500 mg dose …

… pneumonia patients and two patients with other indications. … cefepime or ceftazidime and
piperacillin/tazobactam, 58.9% … or ceftazidime and piperacillin/tazobactam and carbapenems. …

… between nonobese and obese patients treated with 1 gram of ertapenem daily. While this
study supports the use of a standard dose of ertapenem in obese patients for the treatment of …

… further modifications and when defining dose regimens in these ICU patients. For
example, it … among patients with complication UTI, meropenem-vaborbactam piperacillin-tazobactam …

… (13 and 20 mg/L for meropenem and piperacillin/tazobactam, respectively) and a high
concentration (43 and 97 mg/L for meropenem and piperacillin/tazobactam, respectively). …

… dosage adjustment and monitoring in the morbidly obese patient population and patients …
Recently, piperacillin/ tazobactam and flucloxacillin have been reported to increase the risk …